Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Fasedienol

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vistagen Completes PALISADE-4 Phase 3 Dosing for Social Anxiety
    Vistagen Completes PALISADE-4 Phase 3 Dosing for Social Anxiety

    08 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-08/vistagen-announces-completion-of-last-patient-visit-in-palisade-4-phase-3-public-speaking-challenge

    PHARMIWEB
    08 May 2026
    Share Share
    Vistagen's Social Anxiety Disorder Asset Stumbles In Phase 3
    Vistagen's Social Anxiety Disorder Asset Stumbles In Phase 3

    18 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251217824138/en/Vistagen-Announces-Topline-Results-from-PALISADE-3-Phase-3-Public-Speaking-Challenge-Study-of-Fasedienol-for-the-Acute-Treatment-of-Social-Anxiety-Disorder

    BUSINESSWIRE
    18 Dec 2025
    Share Share
    Vistagen Wraps PALISADE-3 Phase 3 Study For Social Anxiety
    Vistagen Wraps PALISADE-3 Phase 3 Study For Social Anxiety

    03 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103479407/en/Vistagen-Completes-PALISADE-3-Phase-3-Public-Speaking-Challenge-Study-for-the-Acute-Treatment-of-Social-Anxiety-Disorder

    BUSINESSWIRE
    03 Nov 2025
    Share Share
    Vistagen to Release Fasedienol PALISADE-3 Data Q4
    Vistagen to Release Fasedienol PALISADE-3 Data Q4

    02 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250602738861/en/Vistagen-on-Track-to-Deliver-Topline-Data-From-Fasedienol-PALISADE-3-Phase-3-Trial-for-Acute-Treatment-of-Social-Anxiety-Disorder-in-the-Fourth-Quarter-of-This-Year

    BUSINESSWIRE
    02 Jun 2025
    Share Share
    Vistagen Initiates PALISADE-4 Phase 3 Study Of Fasedienol
    Vistagen Initiates PALISADE-4 Phase 3 Study Of Fasedienol

    23 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240923438804/en

    BUSINESSWIRE
    23 Sep 2024
    Share Share
    Vistagen Initiates Ph3 Study of Fasedienol for the Social Anxiety Disorder
    Vistagen Initiates Ph3 Study of Fasedienol for the Social Anxiety Disorder

    01 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240401402849/en

    BUSINESSWIRE
    01 Apr 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.